HomeCompareFRTAY vs JNJ

FRTAY vs JNJ: Dividend Comparison 2026

FRTAY yields 7.31% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRTAY wins by $58191.39M in total portfolio value
10 years
FRTAY
FRTAY
● Live price
7.31%
Share price
$15.01
Annual div
$1.10
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$58191.43M
Annual income
$56,700,628,091.33
Full FRTAY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — FRTAY vs JNJ

📍 FRTAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRTAYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRTAY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRTAY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRTAY
Annual income on $10K today (after 15% tax)
$621.05/yr
After 10yr DRIP, annual income (after tax)
$48,195,533,877.63/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, FRTAY beats the other by $48,195,529,891.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRTAY + JNJ for your $10,000?

FRTAY: 50%JNJ: 50%
100% JNJ50/50100% FRTAY
Portfolio after 10yr
$29095.73M
Annual income
$28,350,316,390.36/yr
Blended yield
97.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FRTAY
No analyst data
Altman Z
2.9
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRTAY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRTAYJNJ
Forward yield7.31%2.13%
Annual dividend / share$1.10$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$58191.43M$30.3K
Annual income after 10y$56,700,628,091.33$4,689.40
Total dividends collected$58089.22M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FRTAY vs JNJ ($10,000, DRIP)

YearFRTAY PortfolioFRTAY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,161$1,461.29$10,592$272.30+$1.6KFRTAY
2$16,334$3,321.72$11,289$357.73+$5.0KFRTAY
3$25,817$8,339.31$12,123$472.89+$13.7KFRTAY
4$52,261$24,636.66$13,141$629.86+$39.1KFRTAY
5$149,137$93,217.76$14,408$846.81+$134.7KFRTAY
6$656,802$497,225.40$16,021$1,151.60+$640.8KFRTAY
7$4,795,845$4,093,066.82$18,122$1,588.22+$4.78MFRTAY
8$60,994,752$55,863,198.07$20,930$2,228.20+$60.97MFRTAY
9$1,393,268,316$1,328,003,931.37$24,792$3,191.91+$1393.24MFRTAY
10$58,191,425,189$56,700,628,091.33$30,274$4,689.40+$58191.39MFRTAY

FRTAY vs JNJ: Complete Analysis 2026

FRTAYStock

freenet AG provides telecommunications, radio and multimedia, mobile communications, mobile Internet, and digital lifestyle services in Germany. It provides a portfolio of services and products primarily in the areas of mobile voice and data services. The Mobile Communications segment offers mobile communications services, such as marketing of mobile communications services, which include voice and data services from the mobile communications network operators; sells and distributes mobile communications devices, as well as offers additional services for mobile data communications and digital lifestyle; and planning, construction, installation, and maintenance services for WiFi networks. The TV and Media segment provides services to end users in the field of DVB-T2 and IPTV; and planning, project management, installation, operation, service, and marketing services for broadcast-related solutions for business clients in the radio and media sectors. The Other/Holding segment offers portal services, such as e-commerce/advertising services; payment services; various digital products and entertainment formats for downloading and displaying, as well as use on mobile devices; communication development solutions, IT solutions, and other services; and voice and data services. The company provides its services under the mobilcom debitel, GRAVIS, MEDIA BROADCAST, klarmobile.de, freenet ENERGY, vitrado.de, FUNK, freenet BASICS, freenet MOBILE, freenet VIDEO, freenet.de, freenet FLEX, freenet TV, waipu.tv, CARMADA, The Cloud, and freenet Business brands. It operates approximately 520 mobilcom-debitel shops and 40 GRAVIS stores. The company sells its products through approximately 400 electronics stores, as well as online platforms. freenet AG was founded in 2005 and is headquartered in Büdelsdorf, Germany.

Full FRTAY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this FRTAY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRTAY vs SCHDFRTAY vs JEPIFRTAY vs OFRTAY vs KOFRTAY vs MAINFRTAY vs ABBVFRTAY vs MRKFRTAY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.